MiRus Launches Major Trial for Novel Nickel-Free Heart Valve System

ATLANTA, GA – April 08, 2026 – Life sciences company MiRus has initiated a pivotal clinical trial for its next-generation heart valve, a move that could significantly alter the landscape of treatment for severe aortic stenosis. The company announced today that the first patients have been successfully enrolled and treated in the STAR Trial, a large-scale study designed to evaluate the Siegel™ Transcatheter Aortic Valve (THV), an investigational device featuring a unique nickel-free alloy and an ultra-low-profile delivery system.

The first procedures were performed at Atlanta's prestigious Piedmont Heart Institute by a team led by Dr. Pradeep K. Yadav and Dr. Vinod H. Thourani, both of whom are national leaders in the trial. The commencement of this study, officially registered as NCT07278310, marks a critical milestone for a device that aims to address some of the lingering challenges in the rapidly evolving field of minimally invasive heart valve replacement.

A Technological Leap in Cardiovascular Implants

The Siegel™ valve system introduces several key innovations that distinguish it from current-generation devices. At the forefront is its 8-French (8-Fr) delivery system. In the world of catheter-based procedures, size is paramount. A smaller catheter, measured in French units, allows for a less invasive procedure, typically through a smaller incision in the groin's femoral artery. This can lead to reduced bleeding risk, fewer vascular complications, and potentially faster patient recovery.

This reduction in size is made possible by the novel material at the valve's core: a nickel-free Rhenium alloy. MiRus, a company whose material science was inspired by NASA's work on rocket engines, pioneered this alloy for its high yield strength, fatigue resistance, and minimal recoil. These properties allow for a strong, durable valve frame that can be compressed into a much smaller catheter without being compromised. The absence of nickel is also a significant clinical advantage, as it eliminates the risk of allergic reactions in patients with nickel sensitivity, a known concern with other medical implants.

"Our initial experience is very positive," commented Dr. Pradeep K. Yadav, who serves as a National Co-Principal Investigator for the trial. "Siegel is much less invasive then current devices and can be placed very precisely due to the lack of foreshortening. This should lead to lower pacemaker rates. The hemodynamics are excellent due to the radial strength and porcine pericardial leaflets."

This lack of foreshortening—the tendency of some valves to shorten in length as they expand—allows for more accurate positioning within the heart's native valve, a critical factor in preventing complications like the need for a permanent pacemaker.

Redefining Patient Care and Expanding Treatment Horizons

Aortic stenosis, a progressive narrowing of the heart's main outflow valve, affects millions of people worldwide, leading to shortness of breath, chest pain, and eventually heart failure if left untreated. While open-heart surgery was once the only option, Transcatheter Aortic Valve Replacement (TAVR) has revolutionized care by offering a minimally invasive alternative.

As TAVR has become the standard of care for patients across all surgical risk levels, the focus has shifted toward refining the technology to improve long-term outcomes, especially as younger and lower-risk patients are now being treated. The STAR Trial is designed to meet this challenge head-on.

"The initiation of this trial marks a critical step toward improving the treatment options for patients with aortic stenosis," said Dr. Yadav. "As TAVR has becomes standard of care across risk profiles, it is vital that we study the next generation of devices and techniques to minimize risks such as stroke, bleeding, pacemaker dependency and optimize valve longevity – especially in younger, lower-risk patients."

The trial is a prospective, multicenter, randomized controlled study set to enroll 1025 patients across the United States. In a direct head-to-head comparison, patients will be randomized to receive either the Siegel™ THV or a commercially available TAVR system from established market leaders. The study's primary endpoint is a composite of mortality, stroke, and cardiovascular-related hospitalization at one year, a robust measure of both safety and effectiveness.

Dr. Vinod H. Thourani, National Co-Chairman of the trial, expressed his enthusiasm for the device's potential. "An 8 French system with such precise placement, low gradients, and no PVL [paravalvular leak] is a combination I never expected in THV. A THV without nickel is also much needed. The STAR trial is the most exciting trial in the management of aortic stenosis in the last decade!"

A New Contender in a High-Stakes Market

The TAVR market is a multi-billion dollar sector dominated by medical device giants. For a privately-held company like MiRus, entering this space requires not just innovative technology but also rigorous clinical data to prove its worth. The comprehensive design of the STAR Trial signals that MiRus is confident in the Siegel™ valve's ability to compete at the highest level.

With unconditional FDA approval to begin the trial granted in late 2025 and subsequent CMS approval in March 2026, the study is now fully underway. The leadership team for the trial includes some of the most respected names in interventional cardiology and cardiac surgery, including Dr. Martin Leon as a chairperson, lending significant credibility to the endeavor. If the Siegel™ valve can demonstrate superior or even equivalent outcomes with the added benefits of a less invasive approach and a nickel-free design, it could significantly disrupt the current market dynamics.

The data from the STAR Trial will be closely watched by clinicians, competing companies, and investors. The study's estimated primary completion date is in late 2028, at which point the full one-year results will provide a clear picture of the Siegel™ valve's performance. Until then, the successful treatment of the first patients represents a promising first step in what could be the next chapter of structural heart therapy.